Expression of HMGB1 and its Clinical Significance in T-cell Lymphoma

Mao, Xing-Jiang; Wang, Geng-Fu; Chen, Zhijun; Wang, Lina; Zhang, Junbiao; Wang, Huiling

doi:10.7314/apjcp.2012.13.11.5569

Cited by 14 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we also found that the positive expression of HMGB1 was significantly increased in the nucleus of gastric cancer tissues compared with the adjacent non-cancer tissues. Similar with other studies (10,(26)(27)(28), HMGB1 was found correlated with metastatic lymph nodes in gastric cancer, suggesting that nuclear accumulation of HMGB1 might be involved in the development and progression.…”

Section: Discussionsupporting

confidence: 90%

“…HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer (25). Expression of HMGB1 is also significantly associated with malignancy and clinical stage of T-cell lymphomas, and may be an important biomarker for the development and progression of T-cell lymphoma (26). The expression of HMGB1 is closely correlated with pathological grade and distant metastases of liver cancer, and knockdown of HMGB1 inhibits liver cancer growth and metastasis, suggesting that HMGB1 may represent a potential therapeutic target for the aggressiveness of this malignancy (27).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo

Zhang

Kou

Zhu

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

High mobility group box 1 (HMGB1) as a novel inflammatory molecule has been shown to be involved in a variety of cell physiological and pathological behaviors including immune response, inflammation and cancer. Evidence suggests that HMGB1 plays a critical role in the development and progression of multiple malignancies. However, the underlying molecular mechanisms for the HMGB1-mediated growth and invasion of gastric cancer have not yet been elucidated. The present study investigated the expression of HMGB1 in gastric adenocarcinoma (GAC) and the mechanisms by which it contributes to tumor growth and invasion. The correlation between HMGB1 expression and clinicopathological characteristics of GAC patients was assessed by immunohistochemical assay through tissue microarray procedures. The RNA and protein expressions of HMGB1 and downstream factors were detected by quantitative PCR and western blot assays; cell proliferation and invasion were determined by MTT, wound-healing and 3D-Matregel assays, subcutaneous SGC-7901 tumor models were established to verify tumor growth in vivo. We demonstrated that, the expression of HMGB1 was significantly increased in the nucleus of GAC tissues compared with that in adjacent non-cancer tissues (88.6 vs.70.5%, P<0.001), and correlated with the metastatic lymph node of GAC (P=0.018). Furthermore, knockdown of HMGB1 by shRNA inhibited cell proliferative activities and invasive potential, and downregulated the expression of NF-κB p65, PCNA and MMP-9 in GAC cells (SGC-7901 and AGS). The tumor volumes in SGC7901 subcutaneous nude mouse models treated with Lv-shHMGB1 was significantly smaller than those of the nonsense sequence group. Taken together, these findings suggest that increased expression of HMGB1 is associated with tumor metastasis of GAC, and knockdown of HMGB1 suppresses growth and invasion of GAC cells through the NF-κB pathway in vitro and in vivo, suggesting that HMGB1 may serve as a potential therapeutic target for GAC.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo

Zhang

Kou

Zhu

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…24reported that survivin is very valuable in differential diagnosis between follicular hyperplasia and neoplasia. Different results were mentioned by (25) and (26) who reported that survivin expression in reactive hyperplasia was (45%) and (10%) respectively.…”

Section: Discussionmentioning

confidence: 78%

Diagnostic and Predictive Value of Survivin, P63 Andcd15 in Non Hodgkin's Lymphomas

Emara

Omar

Mostafa

et al. 2015

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Lymphoid proliferations are thought to be either benign reactive conditions, atypical lymphoid proliferations or malignant lymphomas. NHL's are a diverse group of malignant neoplasms that affect lymphoid tissue, their incidence has risen twofold over the past 10 years. IHC, is now routinely used to confirm the diagnosis of lymphoma. The aim: Is to evaluate the expression of Survivin, P63 and CD15 in different types of reactive lymphoid hyperplasia and lymphoma and their ability to differentiate between some types of them. Also, correlate expression of the above markers as indicators of aggressiveness in NHL's. Methods: A total of selected 80 cases of patients which were previously diagnosed as: 30 cases of Non Hodgkin's lymphoma, 20 cases of Hodgkin's lymphoma, and 30 cases of reactive lymphoid hyperplasia. The sections were stained with H&E and immunohistochemical markers of Survivin, p63 and CD15 separately. Results: Expression of survivin & P63 immunostains in cases of aggressive lymphomas was (61.9%)&(71.4%) which are higher than their expression in cases of indolent lymphomas (38.1%)&(28.6%) respectively. Also, expression of survivin &P63 immunostains in cases of follicular lymphoma was (50%)&(33.3%) which are higher than their expression in cases of atypical lymphoid hyperplasia(40%)&(20%) respectively. P63 was frequently expressed in large cell lymphoma cases (64.2%). None of the cases of CHL demonstrated any P63 expression. CD15 is a specific marker of reed Sternberg cells of CHL and showed no expression in cases of lymphocytic predominance HL. CD15 was also occasionally expressed in cases of large cell lymphomas. Conclusion: survivin and P63markers can be used as immunohistochemical tools in distinguishing follicular lymphoma from lymphoid hyperplasia especially atypical cases. Also, survivin and P63markers can be used as indicator of aggressiveness in NHL cases. CD15 is a specific marker of RS cells of CHL. Also, CD15 is occasionally expressed in cases of large cell lymphomas, so not used alone in differentiation between large cell lymphoma and CHL where morphological distinction is difficult. When adding a P63 immunostaining, the accuracy of distinction between these lesions was increased. so,P63 can be used as a potential tool in the differential diagnosis between these lesions.

show abstract

“…This high-mobility protein, also known as the damage-associated molecular pattern molecule (DAMP) has been previously described in the literature as being elevated in human lymphoma. In addition, lymph nodes in lymphoma were found to overexpress HMGB-1 mRNA (TANG et al, 2010;DEJEAN et al, 2012;MAO et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Markers of inflammation and fibrinolysis in canine lymphoma

Kučer¹,

Kuleš²,

Gotić³

et al. 2018

Vet. arhiv

View full text Add to dashboard Cite

Canine lymphoma is one of the most common haematological neoplasms. Results of a numerous studies indicate the important role of chronic inflammation in the development of cancer. The aim of this study was to determine the concentrations of novel inflammatory biomarkers in canine lymphoma. Fifteen dogs with lymphoma and 15 healthy dogs (control group) participated in this study. The plasma levels of high sensitivity C reactive protein (hs CRP), interleukin-6 (IL-6), high mobility group box-1 (HMGB-1), soluble intercellular adhesive molecule-1 (sICAM-1), plasminogen activator inhibitor-1 (PAI-1) and soluble urokinase receptor of plasminogen activator (suPAR) were measured using canine specific enzyme-linked immunosorbent assay (ELISA). Lactate dehydrogenase activity (LDH) was measured using a spectrophotometric method. Dogs with lymphoma had significantly increased plasma hsCRP, IL-6, HMBG-1, sICAM-1, and LDH compared with the control group. In addition, hsCRP, IL-6, HMBG-1, and suPAR concentrations and LDH activity showed a significant strong positive correlation in the lymphoma group. The data obtained support the role of cytokinemediated inflammation in canine lymphoma, and suggest the possibility that anti-inflammatory therapies might provide a supportive effect. The significant and strong positive correlation between the established (hsCRP, IL-6) and novel (HMGB-1, suPAR) inflammatory biomarkers indicate their potential usefulness in canine lymphoma diagnostics.

show abstract

Expression of HMGB1 and its Clinical Significance in T-cell Lymphoma

Cited by 14 publications

References 9 publications

Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo

Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo

Diagnostic and Predictive Value of Survivin, P63 Andcd15 in Non Hodgkin's Lymphomas

Markers of inflammation and fibrinolysis in canine lymphoma

Contact Info

Product

Resources

About